keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer side effects

keyword
https://www.readbyqxmd.com/read/29142786/extraordinary-clinical-benefit-to-sequential-treatment-with-targeted-therapy-and-immunotherapy-of-a-braf-v600e-and-pd-l1-positive-metastatic-lung-adenocarcinoma
#1
Shuyu D Li, Annia Martial, Alexa B Schrock, Jane J Liu
Background: The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensive Cancer Network (NCCN) for treatment options according to biomarker testing results, sequentially applying the three main modalities (chemotherapy, targeted therapy and immunotherapy) remains an ad hoc practice in clinic. In light of recent FDA approval of dabrafenib and trametinib combination for metastatic NSCLCs with BRAF V600E mutation, one question arises due to insufficient clinical data is if the targeted therapy should be used before immunotherapy in patients with both BRAF V600E and PD-L1 expression...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29130448/a-review-on-the-effects-of-current-chemotherapy-drugs-and-natural-agents-in-treating-non-small-cell-lung-cancer
#2
Chih-Yang Huang, Da-Tong Ju, Chih-Fen Chang, P Muralidhar Reddy, Bharath Kumar Velmurugan
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum...
December 2017: BioMedicine
https://www.readbyqxmd.com/read/29104720/dasatinib-induced-seborrheic-dermatitis-like-eruption
#3
Ryan R Riahi, Philip R Cohen
Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Antitumor agents are often associated with mucocutaneous side effects, including seborrheic dermatitis...
July 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29098029/synergistic-anti-proliferative-and-pro-apoptotic-activities-of-5f-and-cisplatin-in-human-non-small-cell-lung-cancer-nci-h23-cells
#4
Yuchan Li, Wende Li, Wusheng Deng, Yuhong Gan, Kefeng Wu, Jie Sun
Two-drug combination chemotherapy, often including cisplatin and one other drug, remains the standard of care for patients with advanced non-small cell lung cancer (NSCLC). To improve the treatment of late-stage NSCLC and decrease the toxicity of combination chemotherapy, the search for novel drugs remains vigorous. Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic acid (5F), a bioactive compound isolated from the herb Pteris semipinnata L., has previously been shown to induce apoptosis and inhibit proliferation in various cancer cells...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29096667/temporal-and-spatial-dose-distribution-of-radiation-pneumonitis-after-concurrent-radiochemotherapy-in-stage-iii-non-small-cell-cancer-patients
#5
Mohammed Alharbi, Stefan Janssen, Heiko Golpon, Michael Bremer, Christoph Henkenberens
BACKGROUND AND PURPOSE: Radiation pneumonitis (RP) is the most common subacute side effect after concurrent chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer. Several clinical and dose-volume (DV) parameters are associated with a distinct risk of symptomatic RP. The aim of this study was to assess the spatial dose distribution of the RP volume from first occurence to maximum volume expansion of RP. MATERIAL AND METHODS: Between 2007 and 2015, 732 patients with lung cancer were treated in an institution...
November 2, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29078573/nonintubated-video-assisted-thoracic-surgery-lobectomy-for-lung-cancer
#6
Ming-Hui Hung, Shun-Mao Yang, Jin-Shing Chen
Nonintubated video-assisted thoracic surgery (VATS) is now well established and is performed in different institutions as a safe and versatile procedure in selected patients. To share the surgical and anesthetic techniques for nonintubated VATS, we present a 56-year-old female patient who underwent nonintubated VATS left upper lobectomy for primary non-small cell lung cancer. Our patient was sedated in a spontaneous breathing status using a target-controlled infusion of propofol. Additionally, regional anesthesia using intercostal block and left-sided intrathoracic vagal block enabled us to do left upper lobectomy and mediastinal lymph node dissection without difficulty...
2017: J Vis Surg
https://www.readbyqxmd.com/read/29043599/shenyi-capsule-plus-chemotherapy-versus-chemotherapy-for-non-small-cell-lung-cancer-a-systematic-review-of-overlapping-meta-analyses
#7
Xiu-Wei Guo, Nai-Dong Hu, Gui-Zhi Sun, Meng Li, Pei-Tong Zhang
OBJECTIVE: To assist decision-makers interpret and choose among conflicting meta-analyses, as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (, SC) plus chemotherapy versus chemotherapy of non-small cell lung cancer (NSCLC). METHODS: A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC...
October 18, 2017: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/29042416/nicotine-prevents-and-reverses-paclitaxel-induced-mechanical-allodynia-in-a-mouse-model-of-cipn
#8
S Lauren Kyte, Wisam Toma, Deniz Bagdas, Julie A Meade, Lesley D Schurman, Aron H Lichtman, Zhi-Jian Chen, Egidio Del Fabbro, Xianjun Fang, John W Bigbee, M Imad Damaj, David A Gewirtz
Chemotherapy-induced peripheral neuropathy (CIPN), a consequence of peripheral nerve fiber dysfunction or degeneration, continues to be a dose-limiting and debilitating side effect during and/or after cancer chemotherapy. Paclitaxel, a taxane commonly used to treat breast, lung, and ovarian cancers, causes CIPN in 59-78% of cancer patients. Novel interventions are needed due to the current lack of effective CIPN treatments. Our studies were designed to investigate if nicotine can prevent and/or reverse paclitaxel-induced peripheral neuropathy in a mouse model of CIPN, while ensuring that nicotine will not stimulate lung tumor cell proliferation or interfere with the anti-tumor properties of paclitaxel...
October 17, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29024572/radiological-manifestations-of-immune-related-adverse-effects-observed-in-patients-with-melanoma-undergoing-immunotherapy
#9
Parveen Sidhu, Alexander M Menzies, Georgina Long, Matteo Carlino, Shirleen Lorens, Rony Kapoor
Immunotherapy drugs work by stimulating the patient's own immune system to recognize and destroy cancer cells. This subclass of drugs is increasingly administered to patients with advanced melanoma. They are also commonly incorporated into other cancer therapies such as non-small cell lung cancer, renal cancer, head and neck cancers and Hodgkin lymphoma. The most commonly administered immunotherapeutic agents in the treatment of melanoma include programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and a subclass of cytokines...
October 11, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28938637/the-loss-of-function-of-dna-methyltransferase-1-by-sirna-impairs-the-growth-of-non-small-cell-lung-cancer-with-alleviated-side-effects-via-reactivation-of-rassf1a-and-apc-in-vitro-and-vivo
#10
Qi Lai, Yin-Hui Xu, Qiang Chen, Liang Tang, An-Gui Li, Li-Fei Zhang, Chun-Fang Zhang, Jian-Fei Song, Zhen-Zong Du
Hypermethylation of tumor suppressor genes (TSGs) promoters by DNA methyltransferase (DNMT) can be observed in almost all cancers which represent a hallmark of carcinogenesis, including lung cancer. DNMT inhibitors (e.g.5-Aza-CR/CdR) reactivate TSGs to exert anti-cancer activity and have been applied into the clinical. However, it is cytotoxic even at low concentrations, which might be not directly related to DNA methylation. We here investigated an alternative strategy in the lung cancer therapy and aimed to estimate and compare its efficiency and side effects of knockdown of DNMT1 in vitro and in vivo...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28915692/biomarker-analysis-of-the-phase-3-torch-trial-for-first-line-erlotinib-versus-chemotherapy-in-advanced-non-small-cell-lung-cancer-patients
#11
Lucia Kim, Mauro Saieg, Massimo Di Maio, Ciro Gallo, Charles Butts, Fortunato Ciardiello, Ronald Feld, Dengxiao Cheng, Vittorio Gebbia, Marco Angelo Burgio, Yasmin Alam, Simona Signoriello, Antonio Rossi, Natasha Leighl, Paolo Maione, Alessandro Morabito, Geoffrey Liu, Ming-Sound Tsao, Francesco Perrone, Cesare Gridelli
BACKGROUND: The TORCH phase III trial compared the efficacy of first-line erlotinib followed by chemotherapy at progression (experimental arm) with the reverse sequence (standard arm) in unselected advanced non-small cell lung cancer (NSCLC) patients. Here we report biomarker analyses. METHODS: EGFR and KRAS mutation, expression of EGFR family members and of cMET and PTEN and EGFR and ABCG2 germline polymorphisms were tested on tumor tissue or blood samples to either confirm previously proposed predictive role or describe it in an explorative setting...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28912410/-psoriasis-and-psoriatic-arthritis-induced-by-nivolumab-in-a-patient-with-advanced-non-small-cell-lung-cancer
#12
Yasoo Sugiura, Hiroyuki Fujimoto, Munehiro Yamamoto, Hisashi Nomura, Toshinori Hashizume, Osamu Kawai, Norito Araki, Kotaro Kawakami, Hitoshi Sueki, Hisae Fusegawa, Yasuyuki Ohkubo, Etsuo Nemoto
BACKGROUND: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-relatedad verse events. CASE PRESENTATION: A 66-year-oldman without any history of autoimmune disease was referredto our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage III A non-small-cell lung cancer by using bronchoscopic biopsy, computedtomography, andFDG -PET. After a single course of cisplatin andpemetrexed , the tumor size increasedremarkably andthe regimen was changedto nivolumab(3mg/kg every 2 weeks)...
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28911085/a-randomized-open-label-multicenter-phase-3-study-to-compare-the-efficacy-and-safety-of-eribulin-to-treatment-of-physician-s-choice-in-patients-with-advanced-non-small-cell-lung-cancer
#13
N Katakami, E Felip, D R Spigel, J-H Kim, M Olivo, M Guo, H Nokihara, J C-H Yang, N Iannotti, M Satouchi, F Barlesi
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). Patients and methods: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel)...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910804/ebus-tbna-can-distinguish-sarcoid-like-side-effect-of-nivolumab-treatment-from-tumor-progression-in-non-small-cell-lung-cancer
#14
Ségolène Lainez, Claire Tissot, Michèle Cottier, Jean-Michel Vergnon
With the expansion of immunotherapy in the treatment of lung cancer, clinicians have to face new clinical pictures and adapt their practice. We report the case of a 69-year-old man diagnosed with non-small cell lung cancer using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and treated with nivolumab as second-line therapy. After 8 injections of nivolumab, a new CT and PET scan revealed massive growth and increase in metabolism of hilar and mediastinal lymph nodes, whereas the size and metabolism of the left upper lobe lesion were reduced...
September 15, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28900482/study-on-inhibitory-effect-of-maimendong-decoction-and-weijing-decoction-combination-with-cisplatin-on-nci-a549-xenograft-in-nude-mice-and-its-mechanism
#15
Fei Xiong, Miao Jiang, Meijuan Chen, Xiaoxia Wang, Shiping Zhang, Jing Zhou, Ke Li, Yan Sheng, Lian Yin, Yuping Tang, Lihong Ye, Mianhua Wu, Haian Fu, Xu Zhang
MaiMenDong Decoction and WeiJing Decoction (Jin formula) is a traditional Chinese medication that consists of 8 medicinal plants, which recorded in the classical TCM literature Jin Kui Yao Lue and has been utilized in the treatment of lung diseases for hundreds of years in China. The present study aimed to determine the anti-tumor activity and the underlying mechanisms of Jin formula combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC). Xenograft model of NCI-A549 was established in Balb/c nude mice...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28895421/in-vivo-isolation-of-circulating-tumor-cells-in-non-small-cell-lung-cancer-patients-by-cellcollector
#16
L Gasiorowski, W Dyszkiewicz, P Zielinski
In non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) can provide information on patient prognosis and treatment efficacy. Currently CTCs are mostly isolated in vitro from small volumes of patient blood samples. The aim of the study was to assess a medical device for in vivo isolation of CTCs directly from the blood of NSCLC patients. The device was inserted in a cubital vein through a standard cannula for thirty minutes. The interaction of target CTCs with the CellCollector was mediated by an antibody directed against the epithelial cell adhesion molecule...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28895417/the-prognostic-value-of-pre-treatment-thrombocytosis-in-two-cohorts-of-patients-with-non-small-cell-lung-cancer-treated-with-curatively-intended-chemoradiotherapy
#17
G Holgersson, S BergstrOm, A Hallqvist, P Liv, J Nilsson, L WillEn, J Nyman, S Ekman, R Henriksson, M Bergqvist
Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28875330/liposomes-co-loaded-with-6-phosphofructo-2-kinase-fructose-2-6-biphosphatase-3-pfkfb3-shrna-plasmid-and-docetaxel-for-the-treatment-of-non-small-cell-lung-cancer
#18
Nusrat Chowdhury, Imran Vhora, Ketan Patel, Ravi Doddapaneni, Arindam Mondal, Mandip Singh
PURPOSE: Non-small cell lung cancer is the leading cause of cancer related deaths globally. Considering the side effects and diminishing chemosensitivity to chemotherapy, novel treatment approaches are sought. Hence, we aim to develop a liposomal co-delivery system of pDNA expressing shRNA against PFKFB3 (pshPFKFB3) and docetaxel (DTX). METHODS: Cationic DTX liposomes complexed with pshPFKFB3 (PSH-DL) were developed. In vitro cell line studies were performed to evaluate transfection, PFKFB3 mRNA silencing, cytotoxicity, pGP inhibition, and protein markers expression...
November 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28869399/clinical-applications-of-textural-analysis-in-non-small-cell-lung-cancer
#19
Iain Phillips, Mazhar Ajaz, Veni Ezhil, Vineet Prakash, Sheaka Alobaidli, Sarah J McQuaid, Christopher South, James Scuffham, Andrew Nisbet, Philip Evans
Lung cancer is the leading cause of cancer mortality worldwide. Treatment pathways include regular cross-sectional imaging, generating large data sets which present intriguing possibilities for exploitation beyond standard visual interpretation. This additional data mining has been termed "radiomics" and includes semantic and agnostic approaches. Textural analysis (TA) is an example of the latter, and uses a range of mathematically derived features to describe an image or region of an image. Often TA is used to describe a suspected or known tumour...
October 27, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28868009/good-tolerance-to-full-dose-crizotinib-in-a-patient-with-anaplastic-lymphoma-receptor-tyrosine-kinase-rearranged-lung-adenocarcinoma-and-preexisting-renal-impairment
#20
Adeline Rosoux, Fabrice Duplaquet, Sebahat Ocak
BACKGROUND: Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib administration was recently reported, but the physiopathological explanation and the safety in patients with preexisting renal dysfunction are still not clear. CASE PRESENTATION: A 44-year-old female and current smoker was diagnosed with a stage IV lung adenocarcinoma and treated with five lines of chemotherapy during a 4-year period of time...
May 2017: Case Reports in Oncology
keyword
keyword
3577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"